Evotec
Evotec are a R&D biotech that offers accelerating, high value pipeline co-creation partnerships and comprehensive CRO/CDMO services – always striving for highest quality, capital efficient execution of R&D programs from disease understanding towards IND, Phase 1, and beyond. Our expertise spans across therapeutic/disease areas and most modalities, especially small molecules and biotherapeutics. We take pride in acting as "drug hunters" in deep collaboration with our partners to advance science. At the core of our operations are our industrialized, AI-powered proprietary R&D platforms, including PanOmics and iPSC technologies. These platforms are instrumental in enhancing disease understanding and ensuring human relevance in our research. By integrating AI and continuous manufacturing technology, we facilitate better access to high-quality biotherapeutics, revolutionizing the way treatments are developed and produced.
Latest Content
Evotec-Partner Bayer Starts Phase 2 Study for Alport Syndrome
Oligonucleotide Solutions from Target ID and Validation to IND
Transforming Drug Discovery With Oligonucleotide Therapeutics
Evotec Announces Progress in Preclinical Neuroscience Partnership With Bristol Myers Squibb
Uncovering Novel Drug Targets for Autoimmune and Inflammatory Diseases
Insights Into the Acute Central Nervous System Responses to Oligonucleotide Delivery
Designing the Future of Multiomics Research
Achieve Exceptional Longitudinal Performance in Clinical Plasma Proteomics
Unlocking High-Value Targets: The Power of Chemoproteomics and Covalent Mass Spectrometry